United States Food and Drug Administration (USFDA) has granted approval to UK-based Circassia Pharmaceuticals' DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) product for the treatment of chronic obstructive pulmonary disease, it was reported yesterday.
The product is a fixed-dose LAMA/LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and the long-acting beta agonist (LABA) formoterol, administered via a PRESSAIR multi-dose inhaler. The product is approved globally, including in the European Union, under various brand names.
David Acheson, Senior Vice President, US Commercial, Circassia, said, 'Our collaboration with AstraZeneca throughout the DUAKLIR PRESSAIR regulatory process has been overwhelmingly positive. We look forward to bringing DUAKLIR PRESSAIR to market in the coming months as an important expansion of Circassia's COPD and respiratory health portfolio.'
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib